
From presenting patient stories and advocacy perspectives to conversations about narcolepsy awareness, LGBTQ+ sleep health, brain fog, and diagnostic delays-—we were proud to bring patient voices and Project Sleep’s work to the forefront. Between Flygare and Manuli, they participated in seven sessions during the conference.
Project Sleep was especially thrilled to be present for the historic clinical trial results shared for orexin agonists. Takeda unveiled Phase 3 data for oveporexton (TAK-861) showing remarkable improvements in wakefulness, cataplexy, symptom severity, and quality of life for people with narcolepsy type 1. Alkermes also reported positive Phase 2 Vibrance-1 results for alixorexton, demonstrating clinically meaningful gains in wakefulness, cognition, and fatigue—all with once-daily dosing.
We left inspired by meaningful conversations and advancements that will shape the future of sleep health and equity worldwide. Thank you to everyone who connected with us during this unforgettable event! See photos and more below.









